Avadim Technologies Inc. (“Avadim”), the Bionome TherapiesTM life sciences company, today announced that is has partnered with Cardinal Health (NYSE: CAH), a global leader in healthcare services and products, to provide Avadim’s line of topical bionome therapies, Theraworx®, to Cardinal Health’s customers. Together, Avadim and Cardinal Health’s Dover™ urological portfolio will deliver overall infection prevention solutions for catheter-associated urinary tract infections (CAUTI) and complications associated with urinary and fecal incontinence.
Through
its microbiome compliant approach, Theraworx® Technology is engineered to
support the skin’s ecosystem, which proactively defends against hospital
acquired conditions - dramatically enhancing quality of life for a lifetime.
When the skin’s natural ecosystem, the microbiome, breaks down, it creates an
environment that opens the door to disease and infection. Theraworx’®
microbiome compliant technology is the industry leader in providing clinically
effective solutions that do not negatively affect the skin’s natural flora,
which human beings depend on to stay alive. Clinical evidence of Theraworx®
Technology’s improved outcomes in a urology setting can be found in a
peer-reviewed abstract, which was recently presented at the American Urological
Association Annual Scientific Meeting this past May.
“We
are honored to partner with one of the most influential leaders in healthcare
across the globe,” said Steve Woody, Chairman and CEO of Avadim Technologies.
“Cardinal Health’s commitment to improving healthcare for more people, in more
ways, and in more places than ever before is directly aligned with our
company’s mission to serve others. It is through this partnership that we hope
to bring our microbiome patented solutions to the millions of individuals who
suffer every day from urogenital complications via the vast Cardinal Health
customer-base, and we look forward to diligently working with their global team
to improve clinical outcomes in acute and Long-Term Care customers everywhere.”
No comments:
Post a Comment